Notice of results, AGM and investor presentation

RNS Number : 3264V

Deltex Medical Group PLC

13 April 2021

 

Tuesday 13 April 2021

Deltex Medical Group plc  

("Deltex Medical" or the "Group")

Announcement of year end results, AGM and investor presentation

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, announces today that it intends to publish its results for the year ended 31 December 2020 on Thursday 22 April 2021.

It also intends to hold the Annual General Meeting at 11.00 am on Thursday 27 May 2021 at its premises at Terminus Road, Chichester PO19 8TX. In line with government advice, Deltex Medical discourages shareholders from attending the AGM in person, but at the same time would strongly encourage shareholders to vote by proxy.

Following the AGM Andy Mears, CEO, will provide a live presentation related to a Company Update via the Investor Meets Company platform on 27^th May 2021 at 12:00pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Deltex Medical Group PLC (DEMG) via:

https://www.investormeetcompany.com/deltex-medical-group-plc/register-investor

Investors who already follow DEMG on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Deltex Medical Group plc	01243 774 837
Nigel Keen, Chairman	[e-mail]
Andy Mears, Chief Executive
David Moorhouse, Group Finance Director
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Ben Cryer Paul Shackleton Dan Gee-Summons	[e-mail]
Joint Broker
Turner Pope Investments (TPI) Ltd	0203 657 0050
Andy Thacker	[e-mail]

Zoe Alexander

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology, TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently save hospitals the costs of treating those complications.

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Group goal

Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia protocol for surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and via agreements with approximately 40 distributors overseas.

 

END

 

 

NORBBGDSCGBDGBX